A new medication, pemafibrate, lowered triglyceride levels among adults with Type 2 diabetes yet did not decrease their cardiovascular risk, according to late-breaking science research presented today ...
In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most patients by more than 60%. Called DR10624, the medication activates three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results